{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-001408","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.825437+00:00","generated_at":"2026-05-28T08:23:44.536395+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch","bullets":["LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.","Secured commercial supply agreements with CMOs; first-year launch supply already produced.","Submitted J-code application under HCPCS; secured inclusion in NCCN guidelines.","Designing patient assistance program and building specialized sales team for CTCL providers.","Exploring international licensing partnerships and expanded indications, including combination immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-001408","json":"https://secwatch.observer/filing/0001213900-25-001408.json","markdown":"https://secwatch.observer/filing/0001213900-25-001408.md","text":"https://secwatch.observer/filing/0001213900-25-001408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025001408/0001213900-25-001408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025001408/ea0226990-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:23:44.536395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}